Orforglipron (Foundayo)

Oral SMD GLP-1 RA · Eli Lilly

Top dose
17.2 mg (tablet) / 36 mg (capsule)
Weight loss
-12.4%
at week 72 · efficacy
AE discontinuation
8.0%
Status
approved

Weight loss trajectory #

Weight loss trajectory for Foundayo 17.2 mg (tablet) / 36 mg (capsule) over 72 weeks in the ATTAIN-1 trial.

Pivotal trial #

Trial
ATTAIN-1
Indication
obesity (no T2D)
Duration
72 weeks
ClinicalTrials.gov
NCT05869903
Sponsor
Eli Lilly

Dose-response: weight loss vs AE-led discontinuation #

Per-arm efficacy (bars, left axis) and AE-led discontinuation (dots, right axis) from ATTAIN-1 (Wharton NEJM 2025). Higher doses generally trade extra weight loss for worse tolerability.

Notes #

First oral SMD GLP-1 approved obesity. No food/water restriction.